This inventor holds 2 USPTO granted patents. Top assignee: Rigel Pharmaceuticals, Incorporated. Active years: 2010-2011.
Company Filing History:
Years Active: 2010-2011
Title: Mark Markovtsov: Innovator in Antiproliferative Compounds
Introduction
Mark Markovtsov is a notable inventor based in Foster City, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with antiproliferative activity. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
Markovtsov's latest patents include innovative 2,4-pyrimidinediamine compounds. These compounds are designed to have antiproliferative activity, which is crucial in inhibiting cellular proliferation. The disclosures detail compositions that comprise these compounds and methods for using them to treat proliferative diseases, such as tumorigenic cancers.
Career Highlights
Mark Markovtsov is currently associated with Rigel Pharmaceuticals, Incorporated, where he continues to push the boundaries of pharmaceutical research. His work focuses on creating effective treatments that can significantly impact patient outcomes in oncology.
Collaborations
Throughout his career, Mark has collaborated with talented individuals such as Hui Li and Ankush Argade. These partnerships have fostered a collaborative environment that enhances innovation and research productivity.
Conclusion
Mark Markovtsov's contributions to the field of pharmaceuticals, particularly in developing antiproliferative compounds, highlight his role as an influential inventor. His work not only showcases his innovative spirit but also holds promise for future advancements in cancer treatment.